Book Text

REFERENCES

1. Martyn JAJ, White DA, Gronert GA, et al: Up-and-down regulation of skeletal muscle acetylcholine receptors. Anesthesiology 76:822, 1992.

2. Naguib M, Flood P, McArdle JJ, Brenner HR: Advances in neurobiology of the neuromuscular junction: Implications for the anesthesiologist. Anesthesiology 96:202, 2002.

3. Drachman DB: Myasthenia gravis. N Engl J Med 330:1797, 1994.

4. Vincent A, Dalton P, Clover L, et al: Antibodies to neuronal targets in neurological and psychiatric diseases. Ann N Y Acad Sci 992:48, 2003.

5. Bowman WC, Prior C, Marshall IG: Presynaptic receptors in the neuromuscular junction. Ann N Y Acad Sci 604:69, 1990.

6. Fletcher GH, Steinbach JH: Ability of depolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors. Mol Pharmacol 49:938, 1996.

7. Paul M, Kindler CH, Fokt RM, et al: Isobolographic analysis of non-depolarising muscle relaxant interactions at their receptor site. Eur J Pharmacol 438:35, 2002.

8. Sanes JR, Lichtman JW: Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2:791, 2001.

9. Lukas RJ, Bencherif M: Heterogeneity and regulation of nicotinic acetylcholine receptors. Int Rev Neurobiol 34:25, 1992.

10. Kelly RB: The cell biology of the nerve terminal. Neuron 1:431, 1988.

11. Marques MJ, Conchello JA, Lichtman JW: From plaque to pretzel: Fold formation and acetylcholine receptor loss at the developing neuromuscular junction. J Neurosci 20:3663, 2000.

12. Taylor P, Schumacher M, MacPhee-Quingley K, et al: The structure of acetylcholinesterase: Relationship to its function and cellular disposition. Trends Neurosci 10:93, 1987.

13. Catterall WA: Structure and functions of voltage-gated ion channels. Annu Rev Biochem 64:493, 1995.

14. Personius KE, Balice-Gordon RJ: Activity-dependent editing of neuromuscular synaptic connections. Brain Res Bull 53:513, 2000.

15. Buttner-Ennever JA, Horn AK: Oculomotor system: A dual innervation of the eye muscles from the abducens, trochlear, and oculomotor nuclei. Mov Disord 2:S2, 2002.

16. Durant NN, Katz RL: Suxamethonium. Br J Anaesth 54:195, 1982.

17. Vachon CA, Warner DO, Bacon DR: Succinylcholine and the open globe. Tracing the teaching. Anesthesiology 99:220, 2003.

18. Betz WJ, Caldwell JH, Kinnamon SC: Increased sodium conductance in the synaptic region of rat skeletal muscle fibers. J Physiol (Lond) 352:189, 1984.

19. Yu FH, Catterall WA: Overview of the voltage-gated sodium channel family. Genome Biol 4:207, 2003.

20. Goudsouzian NG, Standaert FG: The infant and the myoneural junction. Anesth Analg 65:1208, 1986.

21. Heuser JE, Reese TS: Structural changes after transmitter release at the frog neuromuscular junction. J Cell Biol 88:564, 1981.

22. Rash JE, Walrond JP, Morita M: Structural and functional correlates of synaptic transmission in the vertebrate neuromuscular junction. J Electron Microsc Tech 10:153, 1988.

23. Littleton JT, Sheng M: Neurobiology: Synapses unplugged. Nature 424:931, 2003.

24. Wood SJ, Slater CR: Safety factor at the neuromuscular junction. Prog Neurobiol 64:393, 2001.

25. Hall Z, Merlie JR: Synaptic structure and development: The neuromuscular junction. Cell 72:99–121, 1993.

26. Katz B, Miledi R: Estimates of quantal content during "chemical potentiation" of transmitter release. Proc R Soc Lond [Biol] 215:369, 1979.

27. Uchitel OD, Protti DA, Sanchez V, et al: P-type voltage dependent calcium channel mediates presynaptic calcium influx and transmitter release in mammalian synapses. Proc Natl Acad Sci U S A 89:3330, 1992.

28. Waterman S, Pinto A, Lang B, et al: The role of autoantibodies in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 84:596, 1998.

29. Südhof TC: The synaptic vesicle cycle revisited. Neuron 28:317, 2000.

30. Valtorta F, Jahn R, Fesce R, et al: Synaptophysin (p38) at the frog neuromuscular junction: Its incorporation into the axolemma and recycling after intense quantal secretion. J Cell Biol 107:2717, 1988.

31. Rizolli SO, Betz WJ. All change at the synapse. Nature 423:591, 2003.

32. Augustine GJ, Burns ME, DeBello WM, et al. Proteins involved in synaptic vesicle trafficking. J Physiol (Lond) 520:33, 1999.

33. Jahn R, Hanson PI: SNAREs line up in new environment. Nature 393:14, 1998.

34. Sugita S, Shin OH, Han W, et al: Synaptotagmins form a hierarchy of exocytotic Ca(2+) sensors with distinct Ca(2+) affinities. EMBO J 21:270, 2002.

35. Turton K, Chaddock JA, Acharya KR: Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem Sci 27:552, 2002.

878

36. Heeroma JH, Plomp JJ, Roubos EW, Verhage M: Development of the mouse neuromuscular junction in the absence of regulated secretion. Neuroscience 120:733, 2003.

37. Engel AG, Ohno K, Sine SM: Congenital myasthenic syndromes: Progress over the past decade. Muscle Nerve 27:4, 2003.

38. Abraham RB, Rudick V, Weinbroum AA: Practical guidelines for acute care of victims of bioterrorism: Conventional injuries and concomitant nerve agent intoxication. Anesthesiology 97:989, 2002.

39. Gu Y, Forsayeth JR, Verall S: Assembly of the mammalian muscle acetylcholine receptor in transfected COS cells. J Cell Biol 114:799, 1991.

40. Changeux J-P, Edelstein SJ: On allosteric transitions and acetylcholine receptors. Trends Biochem 19:399, 1994.

41. Kopta C, Steinbach JH: Comparison of mammalian adult and fetal nicotinic acetylcholinic receptors stably expressed in fibroblasts. J Neurosci 14:3922, 1994.

42. Pedersen SE, Cohen JB: D-Tubocurarine binding sites are located at alpha-gamma and alpha-delta subunit interfaces of the nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A 87:2785, 1990.

43. Griesmann GE, McCormick DJ, De Aizpurua HJ, et al: α-Bungarotoxin binds to human acetylcholine receptor α-subunit peptide 185–199. J Neurochem 54:1541, 1990.

44. Gullberg D: Cell biology: The molecules that make muscle. Nature 424:138, 2003.

45. Burden SJ: Building the vertebrate neuromuscular synapse. J Neurobiol 53:501, 2002.

46. Tansey MG, Chu GC, Merlie JP: ARIA/HRG regulates AChR epsilon subunit gene expression at the neuromuscular synapse via activation of phosphatidylinositol 3-kinase and Ras/MAPK pathway. J Cell Biol 134:46, 1996.

47. Barrantes FJ: Muscle end plate cholinoceptors. Pharmacol Ther 38:331, 1988.

48. McCarthy MP, Stroud RM: Conformational states of the nicotinic acetylcholine receptor from Torpedo californica induced by the binding of agonist, antagonists, and local anesthetics. Equilibrium measurements using tritium-hydrogen exchange. Biochemistry 28:40, 1989.

49. Karlin A, DiPaola M, Kao PN, Lobel P: Functional sites and transient states of the nicotinic acetylcholine receptor. In Hille B, Fambrough DM (eds): Proteins of Excitable Membranes. Society of General Physiologists. New York, Wiley Interscience, 1987, p 43.

50. Marban E, Yamagishi T, Tomaselli GF: Structure and function of voltage-gated sodium channels. J Physiol 508:647, 1998.

51. Dionne VE: Two types of nicotinic acetylcholine receptors at slow fibre end-plates of the garden snake. J Physiol 409:313, 1989.

52. Raines DE: Anesthesia and nonanesthetic volatile compounds have dissimilar activities on nicotinic acetylcholine receptor desensitization kinetics. Anesthesiology 84:663, 1996.

53. Sine SM: The nicotinic receptor ligand binding domain. J Neurobiol 53:431, 2002.

54. Gage PW, Hammill OP: Effects of anesthetics on ion channels in synapses. Int Rev Neurophysiol 25:3, 1981.

55. Swope SL, Qu Z, Huganir RL: Phosphorylation of nicotinic acetylcholine receptor by protein tyrosine kinases. Ann N Y Acad Sci 757:197, 1995.

56. Plested CP, Tang T, Spreadbury I, et al: AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 59:1682, 2002.

57. Albuquerque EX, Alkondon M, Pereira EF, et al: Properties of neuronal nicotinic acetylcholine receptors: Pharmacologic characterization and modulation of synaptic function. J Pharmacol Exp Ther 280:1117, 1997.

58. Maelicke A, Coban T, Storch A, et al: Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists. J Receptor Signal Transduc Res 17:11, 1997.

59. Creese R, Head SD, Jenkinson DF: The role of the sodium pump during prolonged end-plate currents in guinea-pig diaphragm. J Physiol 384:377, 1987.

60. Martyn JAJ: Basic and clinical pharmacology of the acetylcholine receptor: Implications for the use of neuromuscular relaxants. Keio J Med 44:1, 1995.

61. Ibebunjo C, Martyn JAJ: Thermal injury induces greater resistance to D-tubocurarine in local than in distant muscles in the rat. Anesth Analg 91:1243–1249, 2000.

62. Ikezu T, Okamoto T, Yonezawa K, et al: Analysis of thermal injury-induced insulin resistance in rodents: Implication of post-receptor mechanism. J Biol Chem 272:25289–25295, 1997.

63. Hirose M, Kaneki M, Yasuhara S, et al: Immobilization depresses insulin signaling in skeletal muscle. Am J Physiol 279:E1235, 2000.

64. Hirose M, Kaneki M, Sugita H, et al: Long-term denervation impairs insulin receptor substrate (IRS)-1-mediated insulin signaling in skeletal muscle. Metabolism 50:216, 2001.

65. Ibebunjo C, Nosek MT, Itani M, Martyn JAJ: Mechanisms for the paradoxical resistance to D-tubocurarine during immobilization-induced muscle atrophy. J Pharmacol Exp Ther 87:443–451, 1997.

66. Hogue C, Itani M, Martyn JAJ: Resistance to D-tubocurarine in lower motor neuron injury is related to increased acetylcholine receptors at the neuromuscular junction. Anesthesiology 73:703, 1990.

67. Missias AC, Chu GC, Klocke BJ, et al: Maturation of the acetylcholine receptor in skeletal muscle: Regulation of the AChR γ-to-epsilon switch. Dev Biol 179:223, 1996.

68. Cohen-Cory S: The developing synapse: Construction and modulation of synaptic structures and circuits. Science 298:770, 2002.

69. Gronert GA: Cardiac arrest after succinylcholine: Mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 94:523, 2001.

70. Fletcher SN, Kennedy DD, Ghosh IR, et al: Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 31:1012, 2003.

71. Herridge MS, Cheung AM, Tansey CM, et al: One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 348:683, 2003.

72. Beeson D, Newland C, Croxen R, et al: Congenital myasthenic syndromes: Studies of the AChR and candidate genes. Ann N Y Acad Sci 841:181, 1998.

73. Gomez CM, Maselli RA, et al: Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. Ann Neurol 51:102, 2002.

74. Witzemann V, Schwartz H, Koenen M, et al: Acetylcholine receptor epsilon-subunit deletion causes muscle weakness and atrophy in juvenile and adult mice. Proc Nat Acad Sci U S A 93:13286, 1996.

75. Altiok N, Altiok S, Changeaux JP: Heregulin-stimulated acetylcholine receptor gene expression in muscle: Requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity. EMBO J 16:717, 1997.

76. Olivetti G, Abbi R, Quaini F, et al: Apoptosis in the failing human heart. N Engl J Med 336:1131, 1997.

77. Yasuhara S, Kanakubo E, Perez M-E, et al: Burn injury induces skeletal muscle apoptosis with activation of caspase pathways in rats. The Carl Moyer Award for the best scientific paper at the Annual Meeting of the American Burn Association 1999. J Burn Care Rehabil 20:462, 1999.

78. Yasuhara S, Perez M-E, Kanakubo E, et al: Skeletal muscle apoptosis following burns is associated with activation of pro-apoptotic signals. Am J Physiol 279:1114, 2000.

79. Lukas RJ, Changeux J-P, Novère NL, et al: International union of pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51:397, 1999.

80. Galzi JL, Changeux JP: Neuronal nicotinic receptors: Molecular organization and regulation. Neuropharmacology 34:563, 1995.

81. Chiodini F, Charpantier E, Muller D, et al: Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology 94:643, 2001.

879

82. Taylor P: Anticholinesterase agents. In Gilman AG, Goodna LS, Rall TW, Murad F (eds): Pharmacological Basis of Therapeutics, 9th ed. New York, Macmillan, 1996, p 161.

83. Bom A, Clark JK, Palin R: New approaches to reversal of neuromuscular block. Curr Opin Drug Discov Devel 5:793, 2002.

84. Richtsfeld M, Yasuhara S, Blobner M, Martyn JAJ: Chronic administration of pyridostigmine leads to a myasthenia-like with down-regulation of acetylcholine receptors. Young Investigator Award for abstract to be presented at ASCCA at the ASA Annual Meeting, San Francisco, CA, October 2003.

85. Fink H, Yasuhara S, Blobner M, Martyn JA: Up-regulation of acetylcholine receptors during subchronic infusion of pancuronium is caused by a post-transcriptional mechanism related to disuse. Crit Care Med 32:509, 2004.

86. Yanez P, Martyn JAJ: Prolonged D-tubocurarine infusion and/or immobilization causes upregulation of acetylcholine receptors and hyperkalemia to succinylcholine. Anesthesiology 84:384, 1996.